Chemotherapy for Advanced Non-Small-Cell Lung Cancer in Elderly Patients.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 27468123.
- Also identified by DOI 10.1001/jamaoncol.2016.2050.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Do patients above 70 years of age with newly diagnosed advanced non-small-cell lung cancer benefit from platinum-based combination or should they receive non-platinum agents either as single-agent or in combination? For fit elderly patients platinum-based combination is associated with better overall survival, progression-free survival, and objective response rate, however this improvement should be counter balanced against the higher risk of major adverse events (AE).
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Drug-Related Side Effects and Adverse Reactions
- Platinum